Date of Publication: 09-Feb-2026
INTELLIGENCE OVERVIEW
Agency: AEMPS (Spain)/EMA
The European Medicines Agency (EMA) has published the January 2026 Bulletin of the Committee for Medicinal Products for Human Use (CHMP), outlining key opinions, recommendations, and ongoing regulatory activities impacting human medicines in the EU.
The bulletin provides insights into marketing authorisation decisions, variations, extensions, safety-related discussions, and procedural updates, offering valuable visibility into CHMP’s current regulatory priorities.
Industry Impact
For Marketing Authorisation Holders (MAHs) and regulatory teams, the CHMP Bulletin serves as an early signal of regulatory trends, approval dynamics, and lifecycle management expectations. Staying aligned with these updates supports strategic planning, compliance readiness, and informed decision-making across the product lifecycle.
KEYWORDS: Lifecycle Management, Therapeutic Indication, New Medicines
REFERENCE: https://www.aemps.gob.es/informa/boletin-del-comite-de-medicamentos-de-uso-humano-enero-de-2026/